-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Q19wHwtLVGUAOQ0pJskCKtcTXqers9YajHIatDc9vYdIwwI6m/jEaT29xm07sMXM
 DUFjbl5UC59ZSKiqGaH/gQ==

<SEC-DOCUMENT>0000318306-07-000065.txt : 20071226
<SEC-HEADER>0000318306-07-000065.hdr.sgml : 20071225
<ACCEPTANCE-DATETIME>20071226161059
ACCESSION NUMBER:		0000318306-07-000065
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20071226
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20071226
DATE AS OF CHANGE:		20071226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACCESS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		071326735

	BUSINESS ADDRESS:	
		STREET 1:		2600 N STEMMONS FRWY
		STREET 2:		STE 176
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75207
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		2600 N STEMMONS FRWY
		STREET 2:		STE 176
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX CORP/WY
		DATE OF NAME CHANGE:	19831102
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>r8k-237.htm
<DESCRIPTION>FORM 8K
<TEXT>
<html>

  <head>
    <title>Unassociated Document</title>
<!-- Licensed to: Access Pharmaceuticals, Inc.-->
<!-- Document Created using EDGARizer 3.9.9.131 -->
<!-- Copyright 2007 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <div>
        <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
        <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
      </div>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <div>&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1234px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="1029" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div align="center">UNITED STATES <br>SECURITIES AND EXCHANGE
                COMMISSION<br>Washington, D.C.20549</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1234px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="bottom" width="1031" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><strong>FORM
                8-K</strong></div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1233px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="bottom" width="1018" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><strong>CURRENT
                REPORT <br>Pursuant to Section 13 or 15(d) of
                the<br>Securities Exchange Act of 1934</strong></div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1233px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="1025" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">Date
                of
                Report (Date of earliest event reported):&#160;<strong>December 26,
                2007</strong></div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1232px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes;">
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 1028px; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><strong>ACCESS
                PHARMACEUTICALS, INC.</strong></div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 1;">
            <td bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 1028px; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
                <hr style="COLOR: #aca899" align="center" noshade size="1" width="100%">
              </div>
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
              </div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 2; MSO-YFTI-LASTROW: yes;">
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 1028px; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">(Exact
                name of registrant as specified in its charter)</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1070px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes;">
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 33%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><strong>Delaware</strong></div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 33%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><strong>0-9314</strong></div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 16%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><strong>83-0221517</strong></div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 1;">
            <td valign="top" width="406" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
                <hr style="COLOR: #aca899" align="center" noshade size="1" width="100%">
              </div>
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" width="418" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
                <hr style="COLOR: #aca899" align="center" noshade size="1" width="100%">
              </div>
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" width="208" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
                <hr style="COLOR: #aca899" align="center" noshade size="1" width="100%">
              </div>
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
              </div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 2; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="406" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">(State
                or other jurisdiction <br>of incorporation)</div>
            </td>
            <td valign="top" width="418" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">(Commission<br>File
                Number) </div>
            </td>
            <td valign="top" width="208" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">(IRS
                Employer<br>Identification No.) </div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1084px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes;">
            <td valign="bottom" width="438" bgcolor="transparent" style="BORDER-BOTTOM: black 2px solid">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><strong>2600
                Stemmons Freeway, Suite 176<br>Dallas,
                Texas</strong></div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" width="346" bgcolor="transparent" style="BORDER-BOTTOM: #ffffff solid">
              <div style="MARGIN: 0in 0in 0pt">&#160;</div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" width="287" bgcolor="transparent" style="BORDER-BOTTOM: black 2px solid">
              <div style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0pt" align="center"><strong>75207</strong></div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 1;">
            <td valign="top" width="438" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">&#160;</div>
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" width="346" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">&#160;</div>
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" width="287" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">&#160;</div>
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 2; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="438" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">(Address
                of principal executive offices)</div>
            </td>
            <td valign="top" width="346" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">&#160;</div>
            </td>
            <td valign="top" width="287" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0pt" align="center">(Zip
                Code)</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1124px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes;">
            <td valign="bottom" width="444" bgcolor="transparent" style="BORDER-BOTTOM: #ffffff solid">
              <div style="MARGIN: 0in 0in 0pt">Registrant's telephone number, including
                area code:</div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" width="246" bgcolor="transparent" style="BORDER-BOTTOM: black 2px solid">
              <div style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0pt" align="center">&#160;&#160;<strong>(214)
                905-5100</strong></div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
            </td>
            <td valign="bottom" width="434" bgcolor="transparent" style="BORDER-BOTTOM: #ffffff solid">
              <div style="MARGIN: 0in 0in 0pt">&#160;</div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 1; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="444" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">&#160;</div>
            </td>
            <td valign="top" width="246" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">&#160;</div>
            </td>
            <td valign="top" width="434" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1226px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes;">
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 1085px; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 1;">
            <td width="1085" bgcolor="transparent" style="BORDER-BOTTOM: black 2px solid">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 2; MSO-YFTI-LASTROW: yes;">
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 1085px; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">(Former
                name or former address, if changed since last report)
</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1225px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="1081" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">Check the appropriate box below if
                the
                Form 8-K filing is intended to simultaneously satisfy the filing
                obligation of the registrant under any of the following provisions
                (see
                General Instruction A.2. below): </div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1212px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 3%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">/ /</div>
              <div>&#160;</div>
            </td>
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 96%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">Written communications pursuant to
                Rule
                425 under the Securities Act (17 CFR 230.425) </div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1211px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 3%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">/ /</div>
              <div>&#160;</div>
            </td>
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 96%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;">Soliciting
                material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
                240.14a-12) </font></div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="610" style="WIDTH: 1211px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 3%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">/ /</div>
              <div>&#160;</div>
            </td>
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 96%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;">Pre-commencement
                communications pursuant to Rule 14d-2(b) under the Exchange Act (17
                CFR
                240.14d-2(b)) </font></div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
      <table border="0" cellpadding="0" cellspacing="0" width="610" style="WIDTH: 1211px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 3%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">/ /</div>
              <div>&#160;</div>
            </td>
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 96%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;">Pre-commencement
                communications pursuant to Rule 13e-4(c) under the Exchange Act (17
                CFR
                240.13e-4(c)) </font></div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div style="MARGIN: 0in 0in 0pt">&#160;</div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div>
          <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
          <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>ITEM
        5.02&#160;&#160;&#160;&#160;&#160;&#160;DEPARTURE OF DIRECTORS OR PRINCIPAL
</strong></font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>OFFICERS;
        ELECTION OF DIRECTORS;</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>APPOINTMENT
        OF PRINCIPAL OFFICERS.</strong></font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;">(a)
        Effective December 19, 2007, Stephen R. Seiler resigned as President and
        Chief
        Executive Officer of the Company and concurrently resigned from the Company's
        Board of Directors.</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;">(b)
        On
        December 26, 2007, the Company announced that Jeffrey B. Davis, 44, has been
        named by the Board of Directors as the Company's Chief Executive Officer
        effective as of December 26, 2007.</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;">Mr.
        Davis
        became a director in March 2006. Mr. Davis is Chairman of the Board, member
        of
        the Executive Committee and a Chairman of the Compensation Committee of the
        Board. Mr. Davis currently serves as President of SCO Financial Group LLC.
        Previously, Mr. Davis served in senior management at a publicly traded
        healthcare technology company. Prior to that, Mr. Davis was an investment
        banker
        with various Deutsche Bank banking organizations, both in the U.S. and Europe.
        Mr. Davis also served in senior marketing and product management positions
        at
        AT&amp;T Bell Laboratories, where he was also a member of the technical staff,
        and at Philips Medical Systems North America. Mr. Davis is currently on the
        board of MacroChem Corporation, Uluru, Inc. and Virium Pharmaceuticals, Inc.,
        a
        private biotechnology company. Mr. Davis holds a B.S. in biomedical engineering
        from Boston University and an M.B.A. degree from the Wharton School, University
        of Pennsylvania.&#160;</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;">Mr.
        Davis
        is a director of Somanta Pharmaceuticals, Inc. On April 19, 2007, we announced
        we had entered into an agreement to acquire Somanta Pharmaceuticals, Inc.,
        pursuant to the terms of the merger agreement, upon consummation of the
        acquisition, Somanta&#8217;s preferred and common shareholders will receive an
        aggregate of 1.5 million shares of Access&#8217; common stock</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;">SCO
        Financial Group is an affiliate of SCO Capital Partners LLC.&#160;&#160;SCO
        Capital Partners LLC previously served as placement agent in conjunction
        with
        the Company&#8217;s issuance of Series A Cumulative Convertible Preferred
        Stock.&#160;&#160;In exchange for its services as placement agent SCO Capital
        Partners LLC received a warrant to purchase 100,000 shares of Access common
        stock.</font></div>
      <div><br></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>ITEM
        7.01&#160;&#160;&#160;&#160;&#160;&#160;REGULATION FD DISCLOSURE
&#160;</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;">A
        copy of
        the press release issued by us on December 26, 2007 announcing the appointment
        Mr. Davis as Chief Executive Officer is filed as Exhibit 99.1 and is
        incorporated by reference.</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>ITEM
        9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND EXHIBITS
&#160;</strong></font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;">(c)
        Exhibits</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="9%" style="BORDER-BOTTOM: #000000 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;">Number</font></div>
              </td>
              <td align="left" valign="middle" width="1%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td align="left" valign="top" width="52%" style="BORDER-BOTTOM: #000000 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;">Title</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td align="left" valign="middle" width="1%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td align="left" valign="top" width="52%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;">99.1</font></div>
              </td>
              <td align="left" valign="middle" width="1%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td align="left" valign="top" width="52%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;">Press
                  Release dated December 26, 2007 entitled &#8220;Access Pharmaceuticals Appoints
                  Jeffrey B. Davis As CEO&#8221;</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br></div>
    </div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1231px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="1231" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div align="center">SIGNATURES </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="MARGIN: 0in 0in 0pt"><br>Pursuant to the requirements of the
      Securities Exchange Act of 1934, the registrant has duly caused this report
      to
      be signed on its behalf by the undersigned hereunto duly authorized. <br></div>
    <div>&#160;</div>
    <div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1227px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 44%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 152%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">ACCESS PHARMACEUTICALS, INC.</div>
              <div>(Registrant)</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="MARGIN: 0in 0in 0pt"><br>&#160;</div>
    <div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1226px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes;">
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 39%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 5%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 5%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">By: </div>
              <div>&#160;</div>
            </td>
            <td valign="bottom" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 147%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">&#160;/s/ Stephen B. Thompson</div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 1; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="48" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" width="234" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" width="30" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" width="30" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" width="884" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
                <hr style="COLOR: #aca899" align="center" noshade size="1" width="100%">
              </div>
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="MARGIN: 0in 0in 0pt">&#160;</div>
    <div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1223px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes;">
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 56%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 35%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">Stephen B. Thompson</div>
            </td>
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 111%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">&#160;</div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr style="MSO-YFTI-IROW: 1; MSO-YFTI-LASTROW: yes;">
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 56%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div>&#160;</div>
            </td>
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 35%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">Vice President, Chief Financial
                Officer</div>
            </td>
            <td valign="top" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; WIDTH: 111%; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt">&#160;</div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="MARGIN: 0in 0in 0pt"><br>Date:&#160; December 26, 2007<br></div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0pt; TEXT-ALIGN: center" align="center"><br><strong>Exhibit
      Index</strong></div>
    <div>&#160;</div>
    <div><strong>Exhibit No.<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;Description</strong></div>
    <div>&#160;</div>
    <div>99.1<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;Press
      release issued
      by Access Pharmaceuticals, Inc.&#160;dated December 26, 2007.</div>
    <div>&#160;</div>
    <div>
      <table border="0" cellpadding="0" cellspacing="0" width="600" style="WIDTH: 1217px; mso-cellspacing: 0in; mso-padding-alt: 0in 0in 0in 0in">

          <tr style="MSO-YFTI-IROW: 0; MSO-YFTI-FIRSTROW: yes; MSO-YFTI-LASTROW: yes;">
            <td valign="top" width="1217" bgcolor="transparent" style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: #ece9d8; PADDING-TOP: 0in; BORDER-BOTTOM: #ece9d8">
              <div style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center">
                <hr style="COLOR: black" align="center" noshade size="5" width="100%">
              </div>
              <div style="MARGIN: 0in 0in 0pt">
              </div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="MARGIN: 0in 0in 0pt"><br><br><br></div>
  </body>
</html>



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>r8k-238.htm
<DESCRIPTION>PRESS RELEASE, DATED DECEMBER 26, 2007
<TEXT>
<html>

  <head>
    <title>Unassociated Document</title>
<!-- Licensed to: Access Pharmaceuticals, Inc.-->
<!-- Document Created using EDGARizer 3.9.9.131 -->
<!-- Copyright 2007 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><strong>EXHIBIT
      99.1</strong></div>
    <div>&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">{Access
      Letterhead}<br></div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>ACCESS
      NEWS</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong><u>Contact:
      Company</u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#16
0;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<u>Contact: Investor Relations</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Stephen
      B.
      Thompson&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&
#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Donald C.
      Weinberger/Alisa Steinberg (media)</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt;">Vice
      President, Chief Financial
      Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">Wolfe Axelrod Weinberger
      Assoc. </font>LLC</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Access
      Pharmaceuticals,
      Inc.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160
;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
(212) 370-4500</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>&#160;(214)
      905-5100</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&
#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      &#160;Andrew Hellman, CEOcast, Inc. for Access
      Pharmaceuticals</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&
#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      &#160;(212) 732-4300</strong></font></div>
    <div><br></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>ACCESS
      PHARMACEUTICALS APPOINTS JEFFREY B. DAVIS AS CEO</strong></font></div>
    <div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>-
        Stephen R. Seiler Resigns as President and
        CEO</strong>&#160;-</font></div>
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>DALLAS,
      TX, December 26, 2007, Access Pharmaceuticals, Inc. (OTC BB: ACCP)
</strong>announced today that current Chairman Jeffrey B. Davis has been
      appointed to the additional role of CEO. Stephen R. Seiler has resigned as
      President and CEO of the Company for health reasons. Mr. Seiler has also
      resigned from the Board of Directors.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">&#8220;I
      believe that Access has an exciting future with ProLindac&#8482;, MuGard&#8482;, and the
      Cobalamin Vitamin B-12 oral delivery technology. The Company is positioned
      well
      for 2008 to be an eventful year. Access has been a rewarding experience and
      I am
      proud of what has been achieved during the past year,&#8221; noted Mr.
      Seiler.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">The
      Board
      of Directors has appointed Jeffrey B. Davis, the Chairman of the Board, as
      the
      CEO. Mr. Davis said, "On behalf of the Board of Directors and the entire Access
      team, I want to thank Steve for his efforts and achievements at Access this
      year, including the continued clinical development of ProLindac, a signing of a
      European partnership for MuGard, and the recently completed financing.&#8221; Mr.
      Davis added, &#8220;I am excited about Access&#8217; prospects in 2008 and beyond, and look
      forward to working with the organization to build on recent achievements. Key
      among them is the continued development of our novel DACH platinum ProLindac,
      which is in a Phase 2 trial and will initiate multiple additional clinical
      trials next year, to complete ongoing partnering efforts and seek new partners
      for ProLindac, MuGard, and Cobalamin-enhanced products and platforms, and to
      actively expand our shareholder base.&#8221;</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">________________________________</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>About
      Access:</strong><strong>&#160;</strong>Access Pharmaceuticals, Inc. is a
      biotechnology company that leverages its proprietary nano-polymer chemistry
      expertise to develop proprietary products. Access' products include ProLindac&#8482;,
      a novel DACH platinum drug that is currently in Phase 2 clinical testing of
      patients with ovarian cancer and MuGard&#8482; for the management of patients with
      mucositis. The Company also has other advanced drug delivery technologies
      including Cobalamin&#8482;-mediated targeted delivery and oral drug delivery. Access
      has announced the execution of a definitive merger agreement to acquire Somanta.
      The acquisition of Somanta has not yet closed and the closing is subject to
      numerous closing conditions. For additional information on Access
      Pharmaceuticals, please visit our website at
      www.accesspharma.com.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="WIDTH: 100%" align="left">&#160;&#160;&#160;&#160;&#160;&#160;

          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>-More-</strong></font>&#160;&#160;&#160;&#160;&#160;&#160;</div>&#160;&#160;&#160;&#160;</div>
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        <div style="WIDTH: 100%" align="left">&#160;&#160;&#160;&#160;&#160;&#160;
&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Access
          Pharmaceuticals,
          Inc.</strong></font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;

          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Page
            2</strong></font>&#160;&#160;&#160;&#160;</div>
        </div>
      </div>
    </div><br>
    <div><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>About
      ProLindac&#8482;:&#160;&#160;</strong>ProLindac is a novel DACH platinum prodrug which
      has been shown to be active in a wide variety of solid tumors in both
      preclinical models and in human trials. Access believes that ProLindac&#8217;s unique
      molecular design potentially could eliminate some of the toxic side effects
      seen
      in the currently marketed DACH platinum, Eloxatin, which has sales in excess
      of
      $2 billion.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><em>This
      press release contains certain statements that are forward-looking within the
      meaning of Section 27a of the Securities Act of 1933, as amended, and that
      involve risks and uncertainties. These statements include those relating to:the
      identification of a new CEO, clinical trial plans and results for ProLindac,
      the
      execution of license agreements in the future, our ability to raise additional
      funds and our ability to obtain or meet the closing conditions in the merger
      agreement with Somanta Pharmaceuticals, Inc. and applicable regulatory and
      tax
      requirements, and to otherwise complete the merger in a timely manner, yet
      there
      can be no assurances that the closing conditions will be met or waived or that
      the transaction will close. These statements are subject to numerous risks,
      including but not limited Access&#8217; need to obtain additional financing in order
      to continue the clinical trial and operations and to the risks detailed in
      Access&#8217; and Somanta&#8217;s Annual Reports on Form 10-KSB and other reports filed by
      Access and Somanta with the Securities and Exchange
      Commission.</em></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">###</font></div>
    <div><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br></body>
</html>


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
